Pulse Explore Journal Club Debates Trending Researchers

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors | Synapse

October 25, 2019Open Access

View Full Paper

177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors

SDSatya DasTherapeutics Clinical Research TATaymeyah Al‐ToubahMoffitt Cancer Center GEGhassan El‐HaddadMoffitt Cancer Center

Key Points

Key points are not available for this paper at this time.

Abstract

Lu-DOTATATE fits into the treatment sequence for GEP NET patients remains an area of active investigation.

Ask AI

Helpful

Bookmark

Share

View Full Paper

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Das et al. (Fri,) studied this question.

synapsesocial.com/papers/69ff4913831589f3542d816b https://doi.org/https://doi.org/10.1080/17474124.2019.1685381

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.2018 · 23 citations
2The failure of clinical factors to predict long-term toxicity after PRRT in >800 patients - Is a genetic screen needed?2014 · 1 citations
3Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Progressive Grade 3 Neuroendocrine Neoplasms (NEN)2019 · 2 citations
4Lutetium-labelled peptides for therapy of neuroendocrine tumours2012 · 245 citations
5Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors2017 · 609 citations